SEC Form 4 · accession 0001209191-16-095854
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Konstantinos Alataris
Officer — President, CEO · Director
Period of report
Feb 3, 2016
Accepted (ET)
Feb 4, 2016 · 7:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $2.34 | Feb 3, 2016 | A | 200,000 | A | — | Feb 3, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F125% of the total number of shares underlying the stock option vest on February 3, 2017, and the remaining underlying shares vest in equal monthly installments over the following three-year period.